AstraZeneca plans direct New York listing in another blow to UK life sciencesnews2025-09-29T10:34:17+00:00September 29th, 2025|Endpoints News|
Appeals court rejects Novartis’ attempt to block Entresto genericsnews2025-09-26T18:28:20+00:00September 26th, 2025|Endpoints News|
AstraZeneca offers Farxiga, Airsupra discounts on new DTC sitenews2025-09-26T17:58:25+00:00September 26th, 2025|Endpoints News|
Trump’s new tariff threat throws months of deals and negotiations into uncertainty news2025-09-26T16:01:06+00:00September 26th, 2025|Endpoints News|
Get your CVR: Backloaded acquisitions come into focus following Metsera, 89bio dealsnews2025-09-26T13:30:47+00:00September 26th, 2025|Endpoints News|
Crinetics gets first FDA approval as Palsonify is cleared for rare hormonal disordernews2025-09-26T07:23:39+00:00September 26th, 2025|Endpoints News|
Trump threatens 100% tariff on pharma products next week for companies not building in USnews2025-09-26T01:17:24+00:00September 26th, 2025|Endpoints News|
White House weighs broad drug pricing announcementnews2025-09-25T21:10:12+00:00September 25th, 2025|Endpoints News|
Novartis escalates court fight against Maine 340B law news2025-09-25T19:02:51+00:00September 25th, 2025|Endpoints News|
Pfizer’s Metsera deal could spark more M&A for pharmas ‘tiptoeing into obesity’news2025-09-25T14:58:48+00:00September 25th, 2025|Endpoints News|
